ALNYLAM PHARMACEUTICALS, INC. Proceeds from Lines of Credit
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Proceeds from Lines of Credit of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-10-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2022-10-27
- 2022-09-30: Proceeds from Lines of Credit 9 month $0.00.
- 2021-09-30: Proceeds from Lines of Credit 9 month $250.00M.
| Period end | Proceeds from Lines of Credit 9 month |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-10-27 |
| 2021-09-30 | $250.00M 10-Q · filed 2022-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |